Unnamed AATD Program
Alpha-1 Antitrypsin Deficiency (AATD)
Pre-clinicalLead Program
Key Facts
About AlveoGene
AlveoGene is an innovative biotech focused on transforming outcomes for patients with rare respiratory diseases through targeted, inhaled gene therapy. Its core asset is the InGenuiTy™ platform, a next-generation lentiviral vector system designed for high-efficiency transduction of lung epithelial cells, enabling durable expression and repeatable dosing. The company was formed in July 2023 by a consortium of leading UK life science investors and six world-renowned scientific founders from the UK Respiratory Gene Therapy Consortium, leveraging over £72 million in prior grant-funded research.
View full company profileTherapeutic Areas
Other Alpha-1 Antitrypsin Deficiency (AATD) Drugs
| Drug | Company | Phase |
|---|---|---|
| BEAM-302 | Beam Therapeutics | Preclinical |
| WVE-006 | WaVe Life Sciences | Phase 1/2 |
| INBRX-101 | Inhibrx Biosciences | Phase 2 |
| Glassia® (IV AAT) | Kamada | Approved |
| Inhaled AAT (KMA-001) | Kamada | Phase 3 |
| GalNAc Program (SERPINA1 target) | Korro Bio | Discovery |